EGFR and adenocarcinoma: Activating mutations of the epidermal growth factor receptor (EGFR) gene are detected in 15–20% of patients with non-small-cell lung cancer (NSCLC), predominantly in patients with adenocarcinomas, without a smoking history, in women, and Asian patients [1].